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Introduction
Most endocrine therapies for breast cancer treatment and
prevention depend upon inhibiting the proliferative effect
of oestradiol on oestrogen receptor (ER)-positive tumour
or normal mammary epithelial cells. Either oestradiol is
inhibited from binding to ER by antioestrogens, or serum
and tissue oestradiol concentrations are reduced by
ovarian ablation in premenopausal women or by inhibition
of aromatase in postmenopausal women.
Several randomized comparisons of the two approaches to
endocrine therapy (ER blockade and oestradiol
suppression) were conducted using older, less potent AIs.
Two trials that compared aminoglutethimide with tamoxifen
[1,2] showed no differences in rates of response or
duration of response. Two other randomized trials
compared the second-generation AIs formestane and
fadrozole with tamoxifen [3,4] and showed a trend toward
superiority of the AIs over the antioestrogen, but this was
not statistically significant. At their clinical doses, each of
these three AIs reduces aromatase activity by about 90%.
More recently aminoglutethimide was compared with the
third-generation AI letrozole, which suppresses peripheral
aromatase by at least 99% [5]. Letrozole produced a
higher objective response rate and longer time to
progression, indicating the importance of the complete-
ness of aromatase inhibition [6]. However, when two highly
potent AIs were compared (anastrozole and letrozole) [7]
there was no difference between them in the primary
efficacy end-point, namely time to progression, despite the
fact that letrozole achieves slightly more complete inhibition
of aromatase than does anastrozole [5].
It is unlikely that more potent AIs than those currently
available (anastrozole, letrozole and exemestane) will be
developed in the foreseeable future, and thus the three AIs
are the treatments of choice for comparison with ER
blockade to determine the most active type of endocrine
therapy. In nearly all trials AIs have been compared with
the antioestrogen tamoxifen. This is an appropriate choice
of comparator because, despite a large number of clinical
trial comparisons, no other antioestrogen has been found
to be superior to tamoxifen, which was introduced many
years ago [8].
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Abstract
Endocrine therapies act by either blocking or downregulating the oestrogen receptor or by reducing
oestrogen concentrations around and within the cancer cell. In postmenopausal women, oestrogen
suppression is achieved by inhibition of the enzyme aromatase by aromatase inhibitors (AIs). Modern
AIs (anastrozole, letrozole and exemestane) are more potent than earlier ones and suppress
oestradiol levels in plasma to virtually undetectable concentrations. Recent comparisons of AIs with
the most widely used oestrogen receptor blocking drug tamoxifen indicate that, in general, AIs result
in increased response rates and greater durations of response. Here, we summarize data supporting
the difference between the two types of treatment and attempt to account for the underlying
mechanisms that favour AIs.
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Recent clinical trials indicate that the new AIs generally
have greater response rates and increase median time to
progression compared with tamoxifen in patients with
advanced breast cancer [9–12]. These studies included
some patients who had received tamoxifen as adjuvant
therapy, and this might have influenced the superiority of
the AIs. More recently, AIs were also shown to be more
effective in treatment naïve patients in the neoadjuvant
setting [13] and to be superior in preventing relapse as
adjuvant therapy [14–16]. They may also be superior in
preventing breast cancer because they reduce the
incidence of contralateral breast cancer [14,16,17].
More tumour responses to aromatase
inhibitors
Response to endocrine treatments is best tested before
surgery (neoadjuvant studies) or at first relapse, because
in both situations objective tumour measurements can be
taken and there is only minor confounding from previous
treatments. Response rates in randomized trials
comparing AIs with tamoxifen in both clinical situations are
summarized in Table 1. In most trials there were
significantly greater objective response rates (complete
plus partial remissions) and/or rates of clinical benefit
(complete plus partial remissions, and stable disease for
24 weeks or more) for AIs [9–12,18]. One large
randomized trial comparing anastrozole with tamoxifen in
advanced breast cancer found no significant advantage in
terms of objective response or clinical benefit [19]. The
reason for the lack of difference is not clear, but this is the
only trial in which modern AIs did not show a superior
response rate as compared with tamoxifen. Other small
nonrandomized but carefully performed preoperative
studies by the Edinburgh group [20] also found superior
responses to anastrozole and letrozole as compared with
tamoxifen.
Longer duration of responses to aromatase
inhibitors
The duration of effectiveness of AIs and tamoxifen can be
assessed in randomized trials of first-line therapy in
advanced breast cancer. Both anastrozole and letrozole
extend the median time to progression by approximately
2–3 months compared with tamoxifen (Table 1) [9,12]. In
one trial [11] the investigators reported the time to
progression in all patients who had a clinical benefit
response. The median time to progression in this trial for
tamoxifen after clinical benefit was 7 months, whereas it
was 18 months for anastrozole. Currently, no peer
reviewed phase III data are published and available for
exemestane, but the data outlined above indicate generally
longer durations of response to AIs as compared with
tamoxifen. Similar differences in time to progression have
been reported in animal models of human breast cancer.
Long and coworkers [21] transfected MCF-7 cells with
the aromatase gene and transplanted the cells into nude
mice. In this model, tumour development was inhibited for
37 weeks in letrozole treated mice as compared with 16
weeks in tamoxifen treated mice. In a more recent study
[22] the same group demonstrated that continuous
letrozole administration caused longer tumour growth
retardation than did continuous tamoxifen, tamoxifen
Table 1
Response and time to progression in randomized trials comparing aromatase inhibitors and tamoxifen as neoadjuvant therapy or
in advanced breast cancer
Agent  Number of  Response  Clinical benefit  Time to progression 
Reference administered subjects (%) (%) (months)
[9] Letrozole 453 30 49 9.4
Tamoxifen 454 20 38 6.0
[13] Letrozole 154 55 – –
Tamoxifen 170 36 – –
[11] Anastrozole 171 21 59 11.1
Tamoxifen 182 17 46 5.6
[19] Anastrozole 340 33 56 8.2
Tamoxifen 328 33 56 8.3
[11] Anastrozole 121 43 83 –
Tamoxifen 117 31 56 –
[10] Exemestane 61 41 57 –
Tamoxifen 59 17 42 –271
switched to letrozole, or a combination of tamoxifen and
letrozole. Thus, both in women with advanced breast
cancer and in animal models of human breast cancer, the
time to progression (time to secondary resistance) is
delayed longer by AIs than by tamoxifen.
Why are aromatase inhibitors superior to
tamoxifen?
Superficially, one would expect little difference between the
two treatment types because both effectively reduce
oestrogenic stimulation of breast cancer cells. However,
there are clearly major differences in the mechanisms of
action of the two treatments. Greater response rates
indicate that there are a group of tumours that respond to
AIs but not to tamoxifen. Increased time to progression
using AIs suggests that resistance to tamoxifen arises
sooner than does resistance to AIs. Unravelling the
mechanisms responsible for the superiority of AIs is not only
of interest biologically but it may also be help to achieve
further improvements in endocrine therapy in the future.
Neoadjuvant trials are most helpful with respect to
investigating the mechanism responsible for the difference
in effectivess between the two types of treatment because
tissue before, during and immediately after treatment is
available and can be assayed for potential markers of
increased response using a variety of techniques. Clinical
response rates according to ER and progesterone
receptor (PgR) phenotype were reported in a randomized
trial comparing neoadjuvant letrozole with tamoxifen [18].
Increased responses to letrozole were seen, to a similar
degree, in both ER-positive/PgR-positive and ER-positive/
PgR-negative phenotypes, although for the latter pheno-
type the difference between the two treatments was not
significant, possibly because of the small numbers
included (Table 2). When response was related to HER1
(epidermal growth factor receptor) and HER2 (cErbB2)
expression (in ER-positive tumours), higher response rates
to letrozole were again seen in tumours positive for HER1
or HER2 and those negative for both HER1 and HER2.
However, there were fewer responses to tamoxifen in the
ErbB1/ErbB2-positive tumours. One potential explanation
for this is that tamoxifen causes translocation of ER to
oestrogen response elements of cognate genes, allowing
cross-talk between growth factor and steroid pathways. In
contrast, because AIs reduce this interaction as a result of
reduced oestradiol-stimulated ER activation, greater
effectiveness in downregulating ER-dependent signalling
is achieved. Consideration of how this occurs requires a
description of the basic signalling sequence for ER.
Classically, both oestradiol and tamoxifen bind to the ER
and cause dimerization and translocation of the receptor
to the promoter region of oestrogen-regulated genes.
However, whereas oestradiol activates two regions of the
ER molecule (called activating function [AF]1 and AF2),
tamoxifen inhibits AF2 but not AF1. AF1 remains active in
the presence of tamoxifen and thus could be responsible
for the partial agonist activity of the compound. AF1
contains most of the sites that are phosphorylated by
growth factor activity. Tamoxifen and oestradiol cause
conformational changes in the receptor that allow binding
of a series of coactivator and corepressor proteins. It is
thought that the relative proportions of each determine
whether the ligand will act as an oestrogen or an
antioestrogen for a specific gene.
Recent studies suggest that phosphorylation of
coregulators is an additional mechanism of control of
transcription [23]. Ligand-bound ER can also interact with
other transcription factors such as activator protein-1 and
nuclear factor-κB, and other proteins within the cell and
the cell membrane [24]. Thus, there are multiple potential
mechanisms of tamoxifen resistance, but those that
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Table 2
Comparison of oestrogen and progesterone receptor phenotypes with response in a neoadjuvant trial of tamoxifen versus
letrozole
Letrozole Tamoxifen
Phenotype n RR (%) n RR (%) P
ER+/PgR+ 54/85 64 33/81 41 0.005
ER+/PgR– 18/34 53 16/41 39 0.331
ER–/PgR+ 2/4 50 2/2 100 NS
ER–/PgR– 1/12 8 0/16 0 NS
ErbB1 or 2+/ER+ 15/17 88 4/19 21 0.0004
ErbB1 and 2–/ER+ 55/101 54 42/100 42 0.08
ErbB1 or 2+/ER– 0/9 0 0/10 0 –
ER, oestrogen receptor; NS, not significant; PgR, progesterone receptor; RR, response rate. Data from Ellis and coworkers [32].272
depend on receptor dimerization and translocation are
probably of the greatest importance. Resistance may be
caused by increased growth factor activity via AF1 or
alteration of the coactivator/corepressor ratio. An example
of the former mechanism is development of tamoxifen
resistance in MCF-7 cells by transfection with the gene for
the ErbB2 receptor, which can be reversed by blocking
activity of the receptor [25]. Recent examples of the latter
mechanism are the demonstrations that increased
expression of the coactivator AIB1 (activated in breast
cancer 1; also known as SRC3) [26] and decreased
expression of the corepressor [27] are associated with
tamoxifen resistance in women with breast cancer. Other
potential mechanisms of tamoxifen resistance, such as
altered pharmacokinetics, differential cell uptake and
receptor mutation, appear to be less important than was
previously thought [23].
In patients with advanced breast cancer who progress
after a response to tamoxifen, simply stopping tamoxifen
can lead to tumour remission, suggesting that tamoxifen
may be acting as an agonist [28]. Tamoxifen may become
an agonist for MCF-7 cells growing in nude mice [29,30].
Initially, in this model tamoxifen inhibits growth. However,
when these tumours are retransplanted into new mice
tamoxifen treatment stimulates growth. In vitro, cells from
tamoxifen-resistant human pleural effusions have been
shown to be growth stimulated by tamoxifen. Inhibition of
growth can be demonstrated by additional fulvestrant,
suggesting tamoxifen agonist activity occurs via ER
pathways, as expected [31].
By comparison with the multiple potential interactions
after tamoxifen binding and translocation of the ER, the
action of AIs appears relatively simple. It is presumed that
oestradiol levels are reduced to the extent that receptor
dimerization and translocation do not take place to any
appreciable extent. Thus, in the oestrogen responsive
tumour cell, growth is abrogated. Differences in
mechanisms of action of AIs and tamoxifen are exemplified
by changes in transcription of the oestrogen-induced
genes PgR and pS2. In one neoadjuvant study letrozole
reduced expression of PgR and pS2, whereas tamoxifen
resulted in small increases in expression, again indicating
differences from the mechanism of action of AIs [32].
Resistance to AIs has been directly studied in the model
outlined above, in which MCF-7 cells expressing aromatase
were transplanted into nude mice, treated with letrozole and
the time to resistance determined. When the resistant
tumours were retransplanted into new mice their growth
was slowed by tamoxifen and inhibited more effectively by
the pure antioestrogen fulvestrant [21]. Fulvestrant is
thought to act by downregulating ER, and its activity in AI-
resistant tumour suggests that even at low oestradiol
concentrations the ER is active on gene promoters.
Because modern AIs effectively deprive tumour cells of
estrogens, a surrogate method for studying the mechanism
of resistance to oestrogen deprivation is to grow ER-
positive human mammary tumours in oestrogen-depleted
culture medium. When MCF-7 cells are placed in such
media they are growth arrested for 3–6 months and then
begin to regrow. When their response to oestradiol at the
time of regrowth is retested, it is found that the
dose–response curve is shifted to the left and maximal
proliferation occurs at approximately 10–14 mol/l, instead
of the approximately 10–9 mol/l in wild-type MCF-7 cells.
Proliferation at such low levels of oestradiol can be
inhibited by fulvestrant, indicating that hypersensitivity
occurs via an ER-dependent mechanism [33,34].
Resistance to low oestradiol concentrations is associated
with several cellular changes, including enhanced HER2
receptor expression, elevated levels of insulin-like growth
factor-1 receptor and ER, and increased signal
transduction via the mitogen-activated protein kinase and
phosphatidylinositol-3 kinase pathways [34–36].
Recent experiments reported by Santen and colleagues
suggest that resistance to oestrogen deprivation could also
be via membrane associated ER [36]. ER-negative cells
transfected with an ER lacking a nuclear localization signal
and containing a membrane localizing signal proliferated in
response to oestradiol and were inhibited by fulvestrant
and by an inhibitor of GTP-Ras binding to its membrane
receptor (farnesylthiosalicyclic acid). Further studies are
required to determine whether the major mechanism of
hypersensitivity is via membrane ER or nuclear ER, or both.
In the neoadjuvant study in which letrozole was compared
with tamoxifen [37], the ER was quantitated by number of
cells positive and the intensity of staining. Responses to
letrozole were seen in tumours with high ER-positive
scores and the small number of those with low ER scores,
whereas responses were not seen at low receptor scores
with tamoxifen. Thus, this important study suggests that
some of the increased response to AIs is related to their
greater activity not only in tumours that overexpress
growth factor receptors but possibly also in those that
have low expression of ER. Confirmation of these results
and extension to other indicators of response is required
before we can apply these findings clinically. Because
there is a correlation between the presence of HER2 and
low ER levels [38], it will be important to try to separate
the dominant factor in the relationship with tamoxifen
resistance in future studies.
There is also an association between the ER-positive/
PgR-negative tumour phenotype and low cell ER
concentrations. In the ATAC (Arimidex, Tamoxifen Alone
or in Combination) adjuvant therapy trial [39], there was a
relapse-free survival advantage for anastrozole compared
with tamoxifen at a median follow up of 47 months. When
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analyzed according to the two major receptor subgroups,
ER-positive/PgR-positive (74% of patients) and ER-positive/
PgR-negative (17% of patients), although anastrozole was
superior to tamoxifen in both groups there was a much
greater difference in the ER-positive/PgR-negative subtype.
The hazard ratio for the comparison for the ER-positive/
PgR-positive subtype was 0.82 (95% confidence interval
0.65–1.03) in favour of anastrozole, whereas for the
ER-positive/PgR-negative subtype the hazard ratio was
0.48 (95% confidence interval 0.33–0.71). The greater
effect in the ER-positive/PgR-negative subtype may be
related to anastrozole being more effective than tamoxifen
at low receptor concentrations. Also, we know from other
studies that this subtype is more likely to be associated
with HER1/2-positive tumours (approximately 30% express
the nuclear and the cell surface membrane receptor), as
compared with approximately 10% coexpression in the
ER-positive/PgR-positive subtype.
Conclusion
Increased response rates of AIs as compared with
tamoxifen may be related to greater responsiveness to AIs
in tumours with low concentrations of ER and expression
of HER1 and HER2. Delayed resistance to AIs is probably
mediated by a delay in ER binding to gene promoters.
Several biochemical pathways activated during resistance
to tamoxifen and resistance to oestrogen deprivation
suggest new targets for preventing resistance, including
inhibitors of cell surface signal transduction pathways
(inhibitors of phosphatidylinositol-3 kinase and mitogen-
activated protein kinase pathways) and of farnesylation.
Clinical studies combining these agents with AIs herald a
new era of ‘endocrine’ therapy (for a review of this area,
see that by Ellis [40]). These benefits are now being
translated into the adjuvant situation and for prevention of
breast cancer. AIs given immediately after surgery result in
reduced rates of relapse as compared with tamoxifen [14].
AIs given after 2–3 or 5 years of adjuvant tamoxifen confer
additional reductions in relapse compared with tamoxifen
[15,17]. In addition, anastrozole administration results in
fewer contralateral breast cancers as compared with
tamoxifen [14], suggesting that AIs may be used to
prevent breast cancer.
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